Meta Pixel

News and Announcements

A Typical LP Composition In A Venture Fund

  • Published December 14, 2022 8:39AM UTC
  • Publisher Osama Hassan
  • Categories Capital Raising Tips

Do you know what the hardest part of a VC’s journey is?

It’s raising capital for the venture fund itself. 

Founders – take note – you’re not the only ones out there raising capital … 

Let’s continue our journey of understanding the inner workings of VCs … 

VCs depend on limited partners (LPs) for capital. 

Welcome to the world of LPs!

In this universe, you’ll find a range of institutional investors like: 

Foundations, 

University Grants, 

Super/Pension Funds, 

Fund of Funds, 

Family Offices, and

Sovereign Wealth Funds 

Each one has different sources of capital, investment criteria, constraints and return expectations. 

Just as smart founders choose the right VCs and investors on their cap table, the best fund managers pick LPs that matter, can add value and shape their journey. 

The best ones build rich, collaborative, two-way networks. 

To achieve their target returns LPs – institutional investors – have to constantly juggle with different types of assets of which VC is one kind.

Let’s talk about asset classes in another post …

For now, here’s a chart that outlines the typical mix of LPs in a venture fund.

✌️

Click here to view the original Linkedin post.

Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.

Your capital engagement platform

With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now